Ve­ra Ther­a­peu­tics sprints to PhI­II with treat­ment for rare kid­ney dis­ease

Ve­ra Ther­a­peu­tics un­veiled top-line mid-stage da­ta on Tues­day sug­gest­ing its fu­sion pro­tein drug at­aci­cept suc­cess­ful­ly im­proved kid­ney func­tion in pa­tients with a rare au­toim­mune dis­ease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER